Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
L. S. van der Schoot, E. M. Baerveldt, W. A. van Enst, S. P. Menting, M. M. B. Seyger, S. L. Wanders, I. van Ee, A. H. Pieterse, J. M. P. A. van den Reek & E. M. G. J. de Jong. (2023) National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure. Journal of Dermatological Treatment 34:1.
Read now
Read now
Mohamed Ali Babiker Mohamed, Ahmed M. El-Malky, Wael Ahmed Abdelwahab Abdelkarim, Mohamed Abdulmonem Salih Aabdeen, Tarig Hassan Elobid Ahmed, Hassan H. H. Sarsour, Munirah Mohammed Mosa, Yasser S. Amer, Abdulrahman Ali M. Khormi & Abdulmajeed Alajlan. (2022) Evidence-based clinical practice guidelines for the management of psoriasis: systematic review, critical appraisal, and quality assessment with the AGREE II instrument. Journal of Dermatological Treatment 33:6, pages 2771-2781.
Read now
Read now
Mohammad Ibrahim Ahmad Fatani, Issam Ribhi Ahmad Hamadah, Mohammed Abdulaziz Alajlan, Yousef Binamer, Aymen Hamed Salem Alharbi, Amaal Farhan Salman Alruwaili, Maha Abdulrahman Abdulateef Aldayel, Khalidah Ahmed Owdetallah Alenzi, Sultan Mohammed Mubarki, Amr Mohammad Khardaly, Bedor Abdullah Abdulrahman Alomari, Hajer Yousef Almudaiheem, Ahmed Al-Jedai & Maysa Tariq Yousef Eshmawi. (2022) Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). Journal of Dermatological Treatment 33:4, pages 1916-1930.
Read now
Read now
Martin Steinhoff, Alfred F Ammoury, Haytham Mohamed Ahmed, Mohamed Fathy Soliman Gamal & Mahira H El Sayed. (2020) The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East. Psoriasis: Targets and Therapy 10, pages 23-28.
Read now
Read now
Katherine M. Stiff, Katelyn R. Glines, Caroline L. Porter, Abigail Cline & Steven R. Feldman. (2018) Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology 11:12, pages 1209-1218.
Read now
Read now
Anwar Al Hammadi, Afaf Al-Sheikh, Alfred Ammoury, Samer Ghosn, Paolo Gisondi, Issam Hamadah, Abdul-Ghani Kibbi & Khalid Shirazy. (2017) Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. Journal of Dermatological Treatment 28:2, pages 129-135.
Read now
Read now
Articles from other publishers (8)
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, Waleed Alshehhi, Humeira Badsha & Jamal Al‐Saleh. (2022) Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. International Journal of Rheumatic Diseases 25:10, pages 1107-1122.
Crossref
Crossref
Abdulaziz N. Madani, Fahad M. Al-Saif, Lama R. Alzamil, Aljohara M. Almazroua, Nuha A. Alfurayh, Sara D. Aldokhayel, Qais A. Almuhaideb, Nouf S. Alballa, Nujud A. Daham & Abdulrahman A. Alkharashi. (2022) Monitoring the effect of TNF-alpha inhibitors on laboratory parameters and adverse effects in different diseases: a retrospective, single-center study. Annals of Saudi Medicine 42:5, pages 309-318.
Crossref
Crossref
M. E. van Muijen, L. S. van der Schoot, J. M. P. A. van den Reek & E. M. G. J. de Jong. (2021) Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide. Archives of Dermatological Research 314:7, pages 687-695.
Crossref
Crossref
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, Waleed Alshehhi, Humeira Badsha & Jamal Al‐Saleh. (2022)
Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in
UAE
. International Journal of Rheumatic Diseases 25:7, pages 725-732.
Crossref
Crossref
Anwar Al Hammadi, Muna Al Murrawi, Huda R. Ali, Ashraf M. Reda, Hussein A. Dayem, Jawaher Alnaqbi, Zaidoon Abdelhadi, Samir Hantirah, Ayman Alnaeem, Fatima Al. Marzooqi, Amani Alfalasi, Fatima Albreiki, Khadija Aljefri & Faiza Al Ali. (2022) Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis:
Consensus Statements for the United Arab Emirates. New Emirates Medical Journal 3:1, pages 17-34.
Crossref
Crossref
Lara S. van der Schoot, Juul M. P. A. van den Reek, Lynda Grine, Lisa Schots, Wietske Kievit, Jo L. W. Lambert & Elke M. G. J. de Jong. (2021) Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study. Trials 22:1.
Crossref
Crossref
Murlidhar Rajagopalan, Manas Chatterjee, Abhishek De, Sunil Dogra, Satyaki Ganguly, BikashRanjan Kar, Nina Madnani, Shekhar Neema, SG Parasramani, Krina Patel & Sushil Tahiliani. (2021) Systemic management of psoriasis patients in Indian scenario: An expert consensus. Indian Dermatology Online Journal 12:5, pages 674.
Crossref
Crossref
Mina Almasi-Nasrabadi, Reza M. Robati, Omid Zargari & Mohammad Shahidi-Dadras. (2019) Considerable variation among Iranian dermatologists in the knowledge and attitudes regarding the use of biologic agents to manage psoriasis,. International Journal of Women's Dermatology 5:5, pages 356-360.
Crossref
Crossref